Endocrinology

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

The EMDAC voted 10-7 to support the benefit-risks of teplizumab for delaying clinical type 1 diabetes.

The USPSTF has issued the organization's first recommendation on interventions for promoting healthy weight gain during pregnancy and also provided an overview of the evidence base used for the recommendation statement.

A 23-year study suggests presence of autoantibodies could aid clinicians in predicting the risk of developing type 1 diabetes among women with gestational diabetes.

A single-arm study examining the effects of a very-low calorie ketogenic diet over a 1-month period indicates the dietary approach was associated with improvements in body weight and sex hormones among men with overweight or obesity.

An analysis of WHI data indicates social isolation and loneliness were associated with significant increases in risk of major cardiovascular disease, even after adjustment for other clinical risk factors.

A retrospective review of ASCVD risk factors at baseline and 1 year after initiating hormone therapy among transgender adolescents suggests the increased risk of cardiovascular disease seen among this population could be driven by increased prevalence of baseline risk factors.

Pooled data from 10k women in the Lifetime Risk Pooling Project suggests premature menopause was associated with a 40% increase in risk of coronary heart disease.

A comparison of annual mortality rates related to cancer and cardiovascular disease is shedding light on the impact of the obesity epidemic on progress against both since 1999.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

Bigfoot Medical announced the FDA granted 510(k) clearance to the Bigfoot Unity System for use in patients with type 1 or type 2 diabetes aged 12 years and older.

Two studies examining RCTs of herbal and dietary supplements found none of these supplements provided a clinically meaningful reduction in body weight among patients with overweight or obesity.

The smart pen cap system is associated with real-time hypoglycemia alerts and insulin dose recommendations.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

A new study finds the top 10 future research priorities into diabetes and pregnancy.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

New data show dasiglucagon a reliable and rapid treatment in restoring plasma glucose levels.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

Data from more than 1500 general practices are providing a comprehensive overview of the impact of obesity on risk of severe COVID-19 outcomes in England—suggesting each BMI increase beyond 23 kg/m2 increased risk of hospital admission and death.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.